

# Karthikeyan Murugesan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3484655/publications.pdf>

Version: 2024-02-01

26  
papers

874  
citations

840776

11  
h-index

752698

20  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1493  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight, 2019, 4, .	5.0	345
2	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer Discovery, 2021, 11, 282-292.	9.4	132
3	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
4	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. Journal of Clinical Oncology, 2019, 37, 4087-4087.	1.6	42
5	<i>GNAS, GNAQ,</i> and <i>GNA11</i> alterations in patients with diverse cancers. Cancer, 2018, 124, 4080-4089.	4.1	34
6	Evolution and mutations predisposing to daptomycin resistance in vancomycin-resistant Enterococcus faecium ST736 strains. PLoS ONE, 2018, 13, e0209785.	2.5	27
7	Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.. Journal of Clinical Oncology, 2019, 37, 4080-4080.	1.6	25
8	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Modern Pathology, 2021, 34, 1425-1433.	5.5	19
9	Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. Oncologist, 2021, 26, 787-796.	3.7	19
10	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist, 2022, 27, 839-848.	3.7	18
11	Pan-cancer landscape of <i>CD274</i> (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. , 2021, 9, e002680.		13
12	The Coâ€œmutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusionâ€œDriven Cholangiocarcinoma. Hepatology, 2021, 74, 1357-1370.	7.3	13
13	Covalent ERÎ± Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2022, 21, 890-902.	4.1	12
14	<i>IDH1</i> and <i>IDH2</i> Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.. Journal of Clinical Oncology, 2021, 39, 4009-4009.	1.6	11
15	Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape.. Journal of Clinical Oncology, 2020, 38, 3620-3620.	1.6	10
16	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. Oncologist, 2021, 26, 375-382.	3.7	8
17	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precision Oncology, 2021, 5, 1285-1296.	3.0	8
18	Pan-cancer landscape of <i>CD274</i> (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8

#	ARTICLE	IF	CITATIONS
19	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. , 2021, 9, e002558.		7
20	Validation and Characterization of <i>FGFR2</i> Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. Journal of Molecular Diagnostics, 2022, 24, 351-364.	2.8	5
21	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. Oncologist, 2022, 27, 732-739.	3.7	5
22	Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.. Journal of Clinical Oncology, 2019, 37, 2630-2630.	1.6	3
23	Abstract P3-08-02: The frequency and somatic mutation landscape of Fibroblast growth factor receptor ( <i>FGFR</i> ) alterations in breast cancer. Cancer Research, 2022, 82, P3-08-02-P3-08-02.	0.9	2
24	OUP accepted manuscript. Oncologist, 2022, , .	3.7	1
25	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.. Journal of Clinical Oncology, 2021, 39, 2605-2605.	1.6	0
26	Pan-cancer landscape of <i>CD274</i> (PD-L1) and <i>PDCD1LG2</i> (PD-L2) structural variations.. Journal of Clinical Oncology, 2022, 40, 3133-3133.	1.6	0